‘Leclaza can occupy 50% of mkt if used as combination'
By Jung, Sae-Im | translator Kim, Jung-Ju
23.07.27 05:50:17
가나다라
0
Interim results of a Phase III trial that studies Leclaza’s use in combination with Rybrevant will be released in October
Key to competing with Tagrisso... “If the trial succeeds, Leclaza can succeed in the global market”
“Is another level from FLAURA 2 trial...raises expectations on the ‘targeted therapy+targeted therapy’ combo”
Yuhan Corp’s Leclaza (lazertinib) was the first homegrown new drug to be approved as a first-line treatment for EGFR mutation-positive non-small-cell lung cancer. The industry’s eyes are now on how the drug will fare in the global market. Will Leclaza be able to rise as a new contender to AstraZeneca’s ‘Tagrisso (osimertinib)’ that is dominating the global market?
The key lies in the clinical results of 'MARIPOSA', which is being conducted by Janssen. The Phase III MARIPOSA study directly targets the current first-line standard-of-care Tagrisso with Janssen’s ‘Rybrevant (amivantamab)’ and Leclaza combination. If the Rybrevant+Leclaza combination demonstrates a progression-free survival (PFS) superi
Jung, Sae-Im(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)